phenobarbital sodium molecular weight - An Overview
phenobarbital sodium molecular weight - An Overview
Blog Article
pentobarbital will decrease the level or effect of saxagliptin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.
pentobarbital will lessen the level or effect of nisoldipine by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Observe.
buprenorphine subdermal implant and pentobarbital both equally raise sedation. Avoid or Use Alternate Drug. Restrict use to clients for whom alternative treatment choices are insufficient
pentobarbital will reduce the extent or effect of tramadol by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe. Decreased AUC of tramadol plus the Energetic metabolite (O-desmethyltramadol) when coadministered with robust CYP3A4 and CYP2B6 inducers
Contraindicated (1)pentobarbital decreases amounts of panobinostat by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Robust CYP3A4 inducers can lessen panobinostat stages by ~70% and bring about therapy failure.
pentobarbital will reduce the level or effect of roflumilast by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration not encouraged; strong cytochrome P450 enzyme inducers reduce systemic exposure to roflumilast and could lessen the therapeutic effectiveness
pentobarbital will reduce the extent or effect of doravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital decreases amounts of elvitegravir/cobicistat/emtricitabine/tenofovir DF by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. May bring on lack of virologic reaction and possible resistance.
pentobarbital here will reduce the extent or effect of felodipine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.
pentobarbital will decrease the level or effect of ambrisentan by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Mysterious.
Inspection: Parenteral drug goods should be inspected visually for particulate issue and discoloration prior to administration, When solution containers allow. Solutions for injection demonstrating proof of precipitation should not be used.
pentobarbital will reduce the level or effect of zonisamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Importance Unfamiliar.
pentobarbital will decrease the extent or effect of cobimetinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Keep away from coadministration. Sturdy or moderate CYP3A inducers may decrease cobimetinib systemic exposure by >80% and cut down its efficacy.
Anticoagulants: Phenobarbital lowers the plasma amounts of dicumarol (name Earlier used: bishydroxycoumarin) and causes a decrease in anticoagulant exercise as measured because of the prothrombin time. Barbiturates can induce hepatic microsomal enzymes leading to improved metabolism and lessened anticoagulant response of oral anticoagulants (e.